Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human prothrombin complex - CSL Behring

Next Previous
Drug Profile

Human prothrombin complex - CSL Behring

Alternative Names: 4-factor PCC; 4-factor prothrombin complex concentrate; BE 1116; Beriplex; Beriplex P/N; Confidex; Kcentra

Latest Information Update: 13 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Class Blood coagulation factors
  • Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants; Factor VII stimulants; Factor X stimulants; Protein C inhibitors; Prothrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemorrhage

Most Recent Events

  • 28 Mar 2023 Phase-III clinical trials in Haemorrhage (In adolescents, In adults, In the elderly) in USA (IV) (NCT05568888)
  • 18 Oct 2021 CSL plans to initiate a phase III trial in Haemorrhage
  • 30 Sep 2017 Launched for Haemorrhage in Japan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top